PRIMARY PERITONEAL CARCINOMA

This early-stage study is testing a new drug called IMGN151 in patients with recurrent gynecologic cancers that have returned after previous treatments. The main goals are to determine the safest dose, understand how the drug behaves in the body, and see if it shows any early sig…

This study is testing whether a three-drug combination can help the body's immune system fight advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after initial treatment. The treatment includes an immunotherapy drug (pembrolizumab), an investigationa…

This study aims to find the best dose of a new oral drug called sovilnesib for people with advanced ovarian cancer that has stopped responding to standard platinum-based chemotherapy. About 120 participants will take different doses to see which one is safest and shows the most p…

This study is testing whether two immunotherapy drugs, nivolumab alone or combined with ipilimumab, can help control recurrent clear cell ovarian, fallopian tube, and related cancers. It will enroll 46 patients whose cancer has returned after standard chemotherapy. The main goal …

This study is testing a combination of two oral drugs, olaparib and cediranib, to see if they can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is for women whose cancer has returned after previous treatment. The main goals are to see if the dru…

This small pilot study is testing whether a special support program is practical and helpful for women with advanced ovarian cancer. The program includes exercise, nutrition, and stress management, and is given alongside chemotherapy before major surgery. The goal is to see if th…

This study is observing 100 women with breast or gynecological cancers to see if their diet in the month before starting chemotherapy is linked to levels of a blood protein called hepcidin. Researchers will then check if hepcidin levels are connected to how well patients can stic…